Enough is enough–it is time for Congress to address rising insulin prices. Congress has failed to take any action to address the rising cost of insulin. However, the Protecting Access to Biosimilars Act of 2019, introduced by Rep. Diana DeGette (D-CO) in early April, is a promising first step to address the issue. The Energy […]
Surprise Medical Billing Legislation: Issues for Congress to Consider
FACT SHEET Legislative solutions are needed to combat the rising cost of health care in the United States, which accounted for almost 18% of the GDP in 2017. One symptom of the problem, surprise medical bills, contributes to unpredictable, high out-of-pocket costs for consumers. Patients often encounter surprise medical bills when receiving emergency or ancillary […]
NCHC Writes Letter to Senator Alexander on Health Care Costs
On February 28th, NCHC wrote a letter to the Senate HELP Committee addressed to Senator Alexander. The letter was in response to a request from Senator Alexander asking for policy recommendations to address the rising costs of health care. You can read the entire letter here.
NCHC 2019 State Legislative Summary
Governors and state legislatures have been taking action in 2019 to lower health care costs and promote affordable coverage options for their residents. We reviewed 2019 state legislation and executive actions, and highlight some of the boldest approaches to lower drug, provider, and health insurance costs. Please click here to read the report in its […]
NCHC Writes Letter to CMS Supporting CMMI
We recently expressed cautious support for the CMMI Geographic Direct Provider Contracting model in a letter to CMS. New opportunities for physician groups, health plans, and other organizations to partner to serve Medicare, and Medicare and Medicaid dual-eligible beneficiaries could bring new innovations in care delivery to more beneficiaries. As the number of alternative payment […]
The Hill: Is arbitration an answer for high drug prices?
You can read the published op-ed on The Hill here. Future prescription drug costs are projected to spike to unsustainable levels. Biologic pharmaceuticals will make up the majority of new drugs, and unfortunately, they are commonly priced at over five figures for a course of treatment. These drugs promise new breakthroughs in treatments for patients with certain […]
Reflections on Binding Arbitration Briefing
As Congress and the Trump Administration consider policies to address rising prescription drug prices, the National Coalition on Health Care (NCHC) hosted a Capitol Hill briefing on March 15th to put one promising option on the table: the use of binding arbitration in Medicare Part D to determine prices for a limited set of drugs. […]
- 1
- 2
- 3
- …
- 74
- Next Page »